Differential inverse agonist efficacies of SB-258719, SB-258741 and SB-269970 at human recombinant serotonin 5-HT7 receptors

European Journal of Pharmacology
Cécile MahéPhilippe Schoeffter

Abstract

Recombinant 5-hydroxytryptamine 5-HT7 receptors are known to express constitutive, i.e., agonist-independent activity. Nonselective ligands, like methiothepin, ritanserin or clozapine behave as full inverse agonists at 5-HT7 receptors. The aim of the present study was to evaluate the degree of inverse agonist activity of three selective 5-HT7 receptor antagonists ((R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl)propyl]benzene sulfonamide or SB-258719, R-(+)-1-(toluene-3-sulfonyl)-2-[2-(4-methylpiperidin-1-yl)ethyl]-pyrrolidine or SB-258741 and (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)-pyrrolidine-1-sulfonyl)-phenol or SB-269970) in the same model. cAMP accumulation was measured in intact Chinese hamster ovary (CHO) cells expressing human recombinant 5-HT7a receptors. In these cells, 5-HT stimulated cAMP levels and a series of ligands antagonized the effect of 5-HT with a 5-HT7 receptor-like profile. SB-258719 had no inverse agonist activity, SB-258741 behaved as a partial inverse agonist and SB-269970 was a quasi-full inverse agonist (as compared to methiothepin). The inverse agonist effect of SB-269970 was antagonized in a concentration-dependent manner by SB-258719. The widespread spectrum of inverse agonist activiti...Continue Reading

References

Sep 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·M RuatJ C Schwartz
Feb 9, 2000·Trends in Pharmacological Sciences·P VanhoenackerJ E Leysen
May 24, 2000·British Journal of Pharmacology·J J HaganD R Thomas
Feb 7, 2002·Trends in Pharmacological Sciences·Philip G Strange
Mar 13, 2002·Pharmacology, Biochemistry, and Behavior·B PouzetJ Arnt
Mar 22, 2002·British Journal of Pharmacology·Kurt A Krobert, Finn Olav Levy
Mar 1, 1959·British Journal of Pharmacology and Chemotherapy·O ARUNLAKSHANA, H O SCHILD
Jan 15, 2004·Molecular Pharmacology·Terry Kenakin

❮ Previous
Next ❯

Citations

Jun 26, 2012·Disease Models & Mechanisms·Sarah BaxendaleVincent T Cunliffe
Mar 23, 2011·Molecular Neurobiology·Anne MatthysPeter Vanhoenacker
Oct 23, 2013·Pharmacological Reports : PR·Magdalena Jastrzębska-WięsekAnna Wesołowska
Jan 31, 2012·Neuroscience Letters·Maryam S VasefiMichael A Beazely
Jul 15, 2005·Expert Opinion on Pharmacotherapy·Werner Kalow
Dec 1, 2014·BMC Gastroenterology·Konstantinos N TzirogiannisGeorgios I Panoutsopoulos
Sep 10, 2014·European Journal of Pharmacology·Ching-Chia Chang ChienMing-Jai Su
Jul 23, 2011·Journal of Pharmacological Sciences·Alex BrenchatLuz Romero
Mar 11, 2016·PloS One·Martilias S FarrellBryan L Roth
Apr 9, 2005·Medicinal Research Reviews·Willem SoudijnAdriaan P Ijzerman
Jan 30, 2014·Ciência & saúde coletiva·Desirée Sant'Ana HaikalEfigênia Ferreira e Ferreira
Oct 20, 2005·Molecular Pharmacology·Zhongren DingSatya P Kunapuli
Apr 30, 2017·Molecular Neurobiology·Grzegorz SatałaAndrzej J Bojarski
Jan 21, 2020·Neuropharmacology·Philippe De DeurwaerdèreGiuseppe Di Giovanni
Mar 26, 2008·Journal of Medicinal Chemistry·Balázs VolkGyula Simig
Jul 22, 2018·Journal of Medicinal Chemistry·Youngjae KimHyunah Choo
May 25, 2021·Journal of Cardiovascular Pharmacology·Romina Gonzalez-PonsStephanie W Watts
May 6, 2008·Bioorganic & Medicinal Chemistry·Juhee YoonHea-Young Park Choo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here